openPR Logo
Press release

Hyperthermia doubles cancer response rate

03-09-2017 02:56 PM CET | Health & Medicine

Press release from: Dr. Sennewald Medizintechnik GmbH

Munich, March 9, 2017: Clinical data has already demonstrated that adding superficial hyperthermia to radiation in the treatment of recurrent breast cancer and malignant melanoma can double the complete response rate (1). Now a new report published in the "International Journal of Hyperthermia" proves that radiated hyperthermia is the superior method for the treatment of these superficial cancerous tumors.

Hyperthermia, i.e. the heating of tumors to temperatures of 41-45 °C for one hour, is a proven radiosensitizer and chemosensitizer. The superficial form of hyperthermia is applied to tumors infiltrating up to four centimeters into the tissue. Locally recurrent breast cancer (LRBC) is one example of superficial tumor sites for which the effectiveness and safety of combined radiotherapy and hyperthermia has been proven. Only last April, a systematic review and meta-analysis of the results from 34 studies, totaling 2,110 patients, revealed that the overall complete response (tumor eliminated) rate for LRBC increases by 22% to over 60% after adding hyperthermia to radiotherapy. Moreover, in those patients who had been previously irradiated a complete response rate of 66.6% was achieved by combining hyperthermia with reirradiation, without any additional significant treatment morbidity (2).

This increase in clinical outcome as a result of adjuvant hyperthermia is related to the quality of the hyperthermia treatment, i.e. the thermal dose realized in the target region, the goal being 43 °C. Unfortunately, not all methods of hyperthermia are equal.

There are basically two heat delivery methodologies – capacitive and radiated electromagnetic fields. In a recent study at the Department of Radiation Oncology, AMC Academisch Medisch Centrum Amsterdam, Dr. H.P. Kok and Dr. J. Crezee compared the two methods to determine which technique offers the more effective heating characteristics. Not only are there differences between the two heating methods, not all the systems on the market are capable of achieving the required results. For instance, of the five radiated and capacitive hyperthermia systems specifically named in the report, Pyrexar’s BSD-500 system is the only one to have earned FDA approval. This is a portable, fully self-contained radiated system for the treatment of superficial tumors within a few centimeters of the skin surface. It features temperature probes for accurate thermal dosing and monitoring, as well as interchangeable superficial applicators in multiple configurations for treating a range of tumor sizes and locations.

Using their own hyperthermia treatment planning software, the Dutch researchers computed the heat delivery in terms of the specific absorption rate (SAR) and with regard to the temperature distribution. They performed their comparative simulations on a perfused muscle-equivalent phantom and phantoms with a superficial fat layer, assuming a cylindrical superficial target region. Subsequently, they examined a real patient model with a breast cancer recurrence derived from a CT data set, with the target assumed to have muscle-like properties, fat properties or heterogeneous properties in each case.

The results showed that capacitive heating techniques are limited by the fat layer, often resulting in hot spots that cause patient discomfort and prevent the tumor from attaining the temperature necessary for a therapeutic effect. The Pyrexar BSD-500 system uses radiated microwaves at a frequency of 434 MHz to transmit the energy into the body which is absorbed by the tissue as heat, thus reaching the cancer tumor instead of being trapped in the fat layer.

In fact, the researchers observed that radiative hyperthermia yields a temperature in at least 90% of the target volume that is 0.4–1.1 °C higher compared to capacitive heating. This corresponds approximately to a factor 2–4 difference in the thermal dose. Due to the higher tumor temperatures that can be achieved before treatment-limiting hot spots occur, Drs. Kok and Crezee concluded that radiative heating will benefit the clinical outcome.

View the entire report here: http://www.tandfonline.com/doi/abs/10.1080/02656736.2016.1268726?journalCode=ihyt20

(1) Based on published Phase III Clinical Studies
(2) Datta, Niloy R. et al. Hyperthermia and Radiation Therapy in Locoregional Recurrent Breast Cancers: A Systematic Review and Meta-analysis. Int J Radiation Oncol Biol Phys, Vol. 94, No. 5, pp. 1073–1087, 2016

About Dr. Sennewald Medizintechnik:
Dr. Sennewald Medizintechnik GmbH was founded in 1985 by Dr. Gerhard Sennewald in Munich with the goal of discovering trendsetting electro-medical systems providing innovative and beneficial medical treatments and introducing them in Europe. From the beginning, cancer therapy was at the forefront of the company, with a focus on regional and local hyperthermia.

Contact for press enquiries:
Dr. Sennewald Medizintechnik GmbH
Monica Sennewald, Marketing Director
Schatzbogen 86
81829 München
Germany
Tel.: +49 89 542143-25
Fax: +49 89 542143-30
E-mail: mh@sennewald.de
Internet: www.sennewald.de

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Hyperthermia doubles cancer response rate here

News-ID: 461708 • Views: 605

More Releases from Dr. Sennewald Medizintechnik GmbH

32nd ESHO meeting focuses on hyperthermia in the multimodal treatment of cancer …
Munich, May 9, 2018 – The European Society for Hyperthermic Oncology (ESHO) and the Deutsche Gesellschaft für Hyperthermie (DGHT) are holding their 32nd annual meeting in Berlin from May 16 to 19, 2018. As a long-standing Diamond Sponsor of ESHO and the official supplier of hyperthermia systems to Charité Universitätsmedizin Berlin for the past 30 years, Dr. Sennewald Medizintechnik GmbH is proud to once again be part of this important

More Releases for Hyperthermia

Global Deep Hyperthermia Device Industry Market Analysis & Forecast 2018-2023
Global Deep Hyperthermia Device Industry Market Research dispatches in detail investigation of fragments, advertise drivers, imperatives, provincial examination, patterns and conjecture on Deep Hyperthermia Device Market. The market is relied upon to demonstrate consistent development. The examination covers detail investigation, development and estimate of Deep Hyperthermia Device Market. The report incorporates advertise examination on local dimension. The investigation covers chronicled information examination and advertise dependent on income created. Get sample
Global Hyperthermia Instrument Industry Market Analysis & Forecast 2018-2023
Global Hyperthermia Instrument Industry Market Insights and Trends. The presumed organization has finished the top to bottom provide details regarding the Hyperthermia Instrument Market industry, and the far-reaching report center around the momentum patterns of the market and they have additionally anticipated the future market. Global Hyperthermia Instrument Industry Market Report itemized investigation gives data about the present market development rate, and it likewise predicts the future market development rate,
Hyperthermia Treatment for Cancer Market: Competitive Dynamics & Global Outlook …
New report published by Market Research Report Store (MRRS) which offers insights on the global Hyperthermia Treatment for Cancer market. Click to view the full report TOC, figure and tables: https://www.marketresearchreportstore.com/reports/212066/global-hyperthermia-treatment-for-cancer-market Global Hyperthermia Treatment for Cancer Market: Forecast by Type / Application / Region According to this study, over the next five years the Hyperthermia Treatment for Cancer market will register a CAGR in terms of revenue, the global market size will reach
Global Deep Hyperthermia Device Market Professional Survey industry Report 2017
This report studies Deep Hyperthermia Device in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022. Request For Free Sample - https://www.marketresearchhub.com/enquiry.php?type=S&repid=1379070 This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering Pyrexar Medical Celsius Oncotherm Andromedic Vinita Perseon Nanjing Greathope Shanghai Huayuan OrienTech Xianke Medical Equipment BoHua Medical Jilin Orestep
08-08-2017 | Health & Medicine
MRRSE
Global Market Study on Hyperthermia Treatment for Cancer: Microwave Hyperthermia …
Persistence Market Research presents a detailed and all-encompassing report on the hyperthermia treatment for cancer market titled ‘Hyperthermia Treatment for Cancer Market: Global Industry Analysis and Forecast, 2017–2025’. The report starts with an executive summary that states the market overview with pertinent market numbers and forecasts along with the CAGR for the period 2017 to 2025. The executive summary also contains the segment wise forecasts by device type, by end
02-02-2012 | Sports
Omron Healthcare
Running and sweating - natural protection against hyperthermia
Sport and sweating go together. Whether in daily life or during sport activities the production of sweat helps to cool off the body, and is thereby a measure of thermoregulation. A large amount of excess body heat is produced while running - to protect the body from hyperthermia (body overheating), the natural reaction is sweating. However, sweating causes the reduction of water and important minerals; therefore, this loss has to